The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix
This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.
bioRxiv · Jun 15, 2020Microbiology